Take this quiz to show you some of the current Covid-19 treatment recommendations:

Fast Five Quiz: COVID-19 Management

COVID-19 management approaches have evolved to target distinct disease phases. Treatment strategies are usually tailored to address the underlying pathophysiology at different stages of infection.

https://reference.medscape.com/viewarticle/covid-19-management-2025a1000lwj

#Covid19 #CovidTreatment #PublicHealth #Covidisnotover #WearAmask #GetVaccinated

Fast Five Quiz: COVID-19 Management

What do you know about COVID-19 management? Test your knowledge with this quick quiz.

Medscape

処方のみですし、後遺症に関しては情報は書いていないようですが、それでも大変ポジティブなニュースです!🥳
「塩野義製薬、コロナ治療薬で感染予防 治験で効果確認」
https://www.nikkei.com/article/DGXZQOUF296LP0Z21C24A0000000/

About six million asterisks (including no mention of long covid/pasc prevention), but good news nonetheless! 🥳

"Shionogi's Xocova effective in preventing symptomatic COVID-19: study"
https://www.msn.com/en-us/health/other/shionogi-s-xocova-effective-in-preventing-symptomatic-covid-19-study/ar-AA1t9uE2

#CovidIsNotOver #CovidTreatment #Covid #CovidNews #コロナ禍は終わっていません #コロナ治療薬 #コロナ #コロナニュース

塩野義製薬、コロナ治療薬で感染予防 治験で効果確認

塩野義製薬は29日、新型コロナウイルス治療薬「ゾコーバ」の臨床試験(治験)で、感染を予防する効果を確認したと発表した。米国やアフリカ、日本などで患者の同居家族らにゾコーバを投与して発症した割合が、プラセボ(偽薬)を投与した被験者よりも低かった。米国や欧州などでの製造販売の承

日本経済新聞社

From pandemic to endemic: Navigating the new healthcare normal

Anu Osinusi is an infectious disease physician and Vice President of Clinical Research for Hepatitis, Respiratory, and Emerging Viruses at Gilead.

https://youtube.com/shorts/C5DBGpCH3CQ

Listen here: https://kevinmd.com/podcast

#COVIDTransformations #HealthcareEvolution #EndemicPhase #VirusImpact #PatientCare #MortalityRate #UnmetNeeds #AntiviralSolutions #HealthcareChallenge #COVIDTreatment

From pandemic to endemic: Navigating the new healthcare normal

YouTube
‘It’s perfect’: World’s first generative AI-designed COVID drug to start clinical trials

Believed to be the world’s first COVID-19 therapeutic created by generative AI, the drug will soon begin clinical trials, the Canadian-founded company announced

thestar.com

EMA kills #molnupiravir in Europe. EMA's human medicines comittee recommends the refusal of marketing authorization. No clinical benefit.
https://www.ema.europa.eu/en/medicines/human/summaries-opinion/lagevrio

#covid19 #covid #covidtreatment

Lagevrio: Pending EC decision - European Medicines Agency

Lagevrio: Pending EC decision

European Medicines Agency

One more time. 𝗜𝗩𝗘𝗥𝗠𝗘𝗖𝗧𝗜𝗡 𝗗𝗢𝗘𝗦 𝙉𝙊𝙏 𝗧𝗥𝗘𝗔𝗧 𝗖𝗢𝗩𝗜𝗗𝟭𝟵.

New Ivermectin clinical trial just dropped for COVID-19:

•1206 study participants
•600 μg/kg daily for 6 days
•Double-blind, randomized, placebo-controlled platform trial

Drumroll 🥁🥁🥁

IT DIDN'T WORK!!! IT NEVER WORKED!!!

https://jamanetwork.com/journals/jama/fullarticle/2801827

#COVIDisAirborne #Ivermectin #COVID19 #COVID #covidtreatment

Higher-Dose Ivermectin vs Placebo and Time to Sustained Recovery in Outpatients With COVID-19

This platform randomized clinical trial examines the effectiveness of ivermectin at a targeted dose of 600 μg/kg daily compared with placebo for the treatment of early mild to moderate COVID-19.

Yale researchers find potential treatment for COVID-19 brain fog

Early evidence suggests a cocktail of two existing medications could mitigate or eliminate brain fog among patients with long COVID-19, according to researchers at Yale University in New Haven, Conn.

Compound made with B.C. sea sponge offers clues into COVID-19 treatment: UBC

The three most effective compounds come from a sea sponge in Howe Sound, a marine bacteria in Barkeley Sound, and a marine bacteria from Newfoundland.

Global News
An ACE2 decoy irreversibly inactivates SARS-CoV-2, even antibody-resistant variants

I have to admit it: I am very tired of COVID-19, stories about it, and everything related to it. Enough already! I thoroughly do not relish this topic. We all want to move on, even if COVID apparently doesn’t. But I do like to see an innovative...

Daily Kos
How long will it take to understand long COVID?

Researchers have proposed a variety of theories to explain symptoms of COVID long-haulers.

Ars Technica